Preparing for biologic or immunosuppressant therapy

Gastroenterology and Hepatology

Volumn 7, Issue 8, 2011, Pages 544-546

  Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NARCOTIC AGENT; STEROID;

BIOLOGICAL THERAPY; CANCER RISK; DISEASE ACTIVITY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG CONTRAINDICATION; DRUG COST; DRUG MONITORING; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEALTH INSURANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOMA; NOTE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SELECTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 80052642614     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Kane S. Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep. 2010;12:502-506.
2. Morisco F, Castiglione F, Rispo A, et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43(suppl 1):S40-S48.
3. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633.
4. Subramanian V, Finlayson C, Harrison T, Rice P, Pollok R. Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. J Crohns Colitis. 2010;4:199-202.
5. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.